Effect of Liraglutide vs CPAP on Cardiometabolic Outcomes in Obstructive Sleep Apnea

The Benefit of a Liraglutide-based Weight Management Alone or in Addition to Standard CPAP Therapy on Metabolic Function in Patients With Obstructive Sleep Apnoea (OSA) - an Explorative, Proof-of-concept Study

This is an explorative, proof-of-concept study exploring the potential therapeutic role of a Liraglutide-based weight loss regimen versus standard CPAP or the combination of both on metabolic parameters, blood pressure, endothelial function, coronary artery calcification, vascular inflammation and apnea/hypopnea index in non-diabetic patients with moderate to severe obstructive sleep apnea

Inclusion Criteria:

• Newly diagnosed moderate-severe OSA (by standard PSG)
• Body mass index between 30 - 40
• Age 18 - 60 years
• Able to provide written, informed consent

Exclusion Criteria:

• Pregnancy
• Requirement for supplemental oxygen
• Previous diagnosis of OSA or previous CPAP treatment
• Diagnosis of Diabetes
• Previous treatment with GLP-1 analogue
• Previous surgical treatment for obesity
• Active treatment for malignancy or severe psychiatric disorder
• Acute coronary syndrome or stroke within 3 months prior to study
• History of decompensated heart failure
• Professional drivers or drivers with a history of road-traffic accident due to sleepiness
• Severe excessive daytime sleepiness defined as Epworth sleepiness scale >15